Last reviewed · How we verify
Diuretics plus human albumin — Competitive Intelligence Brief
marketed
Diuretic + colloid combination therapy
Hepatology; Nephrology; Critical Care
Small molecule
Live · refreshed every 30 min
Target snapshot
Diuretics plus human albumin (Diuretics plus human albumin) — University of Bologna. Diuretics promote fluid and sodium excretion while human albumin expands plasma volume and maintains oncotic pressure to counteract fluid shifts.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Diuretics plus human albumin TARGET | Diuretics plus human albumin | University of Bologna | marketed | Diuretic + colloid combination therapy |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Diuretic + colloid combination therapy class)
- University of Bologna · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Diuretics plus human albumin CI watch — RSS
- Diuretics plus human albumin CI watch — Atom
- Diuretics plus human albumin CI watch — JSON
- Diuretics plus human albumin alone — RSS
- Whole Diuretic + colloid combination therapy class — RSS
Cite this brief
Drug Landscape (2026). Diuretics plus human albumin — Competitive Intelligence Brief. https://druglandscape.com/ci/diuretics-plus-human-albumin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab